{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:35:52Z","timestamp":1791387352354,"version":"4.3.3"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.bone.2020.115834","type":"journal-article","created":{"date-parts":[[2020,12,23]],"date-time":"2020-12-23T09:56:45Z","timestamp":1608717405000},"page":"115834","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Recombinant human parathyroid hormone (1\u201384) replacement therapy in a child with hypoparathyroidism"],"prefix":"10.1016","volume":"144","author":[{"given":"Elisabeth","family":"Laurer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Gr\u00fcnberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uvistra","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Lanzersdorfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Wimleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Tischlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"H\u00f6gler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2020.115834_bb0005","article-title":"Hypoparathyroidism","author":"Mannstadt","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bone.2020.115834_bb0010","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1210\/jc.2015-3909","article-title":"Presentation of hypoparathyroidism: etiologies and clinical features","volume":"101","author":"Shoback","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0015","doi-asserted-by":"crossref","DOI":"10.4081\/cp.2018.1007","article-title":"Primary hypoparathyroidism presenting as basal ganglia calcification secondary to extreme hypocalcemia","volume":"8","author":"Marques Mendes","year":"2018","journal-title":"Clin. Pract."},{"key":"10.1016\/j.bone.2020.115834_bb0020","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0025","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.bone.2020.115834_bb0030","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0035","series-title":"Journal of Clinical Endocrinology and Metabolism","article-title":"Management of hypoparathyroidism: present and future","author":"Bilezikian","year":"2016"},{"key":"10.1016\/j.bone.2020.115834_bb0040","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1210\/jcem.86.11.8016","article-title":"Activating mutations of the calcium-sensing receptor: management of hypocalcemia","volume":"86","author":"Lienhardt","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0045","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1365-2796.2009.02090.x","article-title":"Clinical manifestations and management of patients with autoimmune polyendocrine syndrome type I","volume":"265","author":"Husebye","year":"2009","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2020.115834_bb0050","doi-asserted-by":"crossref","DOI":"10.1159\/000479867","article-title":"Continuous subcutaneous recombinant parathyroid hormone (1\u201334) infusion in the management of childhood hypoparathyroidism associated with malabsorption","author":"Saraff","year":"2018","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.bone.2020.115834_bb0055","first-page":"869","article-title":"Pharmacokinetics and safety of recombinant human parathyroid hormone (1-34) (teriparatide) after single ascending doses in Chinese healthy volunteers","volume":"62","author":"Chu","year":"2007","journal-title":"Pharmazie."},{"key":"10.1016\/j.bone.2020.115834_bb0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/j.1742-7843.2011.00768.x","article-title":"Safety, tolerability, pharmacokinetics and pharmacodynamics of recombinant human parathyroid hormone after single- and multiple-dose subcutaneous administration in healthy Chinese volunteers","volume":"110","author":"Liu","year":"2012","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.bone.2020.115834_bb0065","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","author":"Linglart","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1\u201334 in children with severe congenital hypoparathyroidism","author":"Winer","year":"2014","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2020.115834_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jpeds.2018.08.010","article-title":"Long-term parathyroid hormone 1\u201334 replacement therapy in children with hypoparathyroidism","volume":"203","author":"Winer","year":"2018","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bone.2020.115834_bb0080","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0085","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0090","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/jbmr.1627","article-title":"Daily parathyroid hormone 1-34 replacement therapy for hypoparathyroidism induces marked changes in bone turnover and structure","volume":"27","author":"Gafni","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115834_bb0095","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1\u201334) versus calcitriol and calcium","author":"Winer","year":"2003","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0100","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1210\/jc.2019-01010","article-title":"Safety and efficacy of 5 years of treatment with recombinant human parathyroid hormone in adults with hypoparathyroidism","volume":"104","author":"Mannstadt","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1\u201384) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.bone.2020.115834_bb0110","series-title":"Paediatric Nephrology","author":"Rees","year":"2019"},{"key":"10.1016\/j.bone.2020.115834_bb0115","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bmj.1.5428.161","article-title":"Effect of variation in dietary calcium on plasma concentration and urinary excretion of calcium","volume":"1","author":"MacFadyen","year":"1965","journal-title":"Br. Med. J."},{"key":"10.1016\/j.bone.2020.115834_bb0120","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.bone.2020.115834_bb0125","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","article-title":"PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment","volume":"28","author":"Sikjaer","year":"2013","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115834_bb0130","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115834_bb0140","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00467-007-0528-9","article-title":"Screening for hypercalciuria in schoolchildren: what should be the criteria for diagnosis?","volume":"22","author":"Koyun","year":"2007","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bone.2020.115834_bb0145","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MOP.0b013e3283223db7","article-title":"Diagnosis and management of hypercalciuria in children","volume":"21","author":"Srivastava","year":"2009","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/j.bone.2020.115834_bb0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1007\/s00467-004-1470-8","article-title":"Idiopathic hypercalciuria in children - how valid are the existing diagnostic criteria?","volume":"19","author":"Butani","year":"2004","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.bone.2020.115834_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1080\/01926230252929882","article-title":"Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety","volume":"30","author":"Vahle","year":"2002","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bone.2020.115834_bb0160","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1080\/01926230601072301","article-title":"Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1\u201384 in a 2-year study in Fischer 344 rats","volume":"34","author":"Jolette","year":"2006","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.bone.2020.115834_bb0165","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1359\/jbmr.061101","article-title":"Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine","volume":"22","author":"Fox","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115834_bb0170","series-title":"Advances in Experimental Medicine and Biology","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-4615-0651-5_17","article-title":"The effects of PTH (1-34) on bone structure and strength in ovariectomized monkeys","author":"Turner","year":"2001"},{"key":"10.1016\/j.bone.2020.115834_bb0175","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1002\/jbmr.1800","article-title":"Safety of osteoanabolic therapy: a decade of experience","volume":"27","author":"Capriani","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2020.115834_bb0180","unstructured":"A. Gilsenan, Kirk Midkiff, D. Harris, N. Kellier-Steele, E.B. Andrews, Results from a fifteen-year postmarketing drug safety surveillance study of adult osteosarcoma and teriparatide in the US, n.d. https:\/\/www.naaccr.org\/wp-content\/uploads\/2017\/07\/Twelve-Year-Study-Update-for-a-Postmarketing-Case-Series-Study-of-Adult-Osteosarcoma-and-Teriparatide-in-the-U.S.-Harris.pdf (accessed June 16, 2020)."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220306220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220306220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:54:15Z","timestamp":1757613255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220306220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":35,"alternative-id":["S8756328220306220"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115834","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recombinant human parathyroid hormone (1\u201384) replacement therapy in a child with hypoparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115834","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115834"}}